Li Watsek
Stock Analyst at Cantor Fitzgerald
(1.31)
# 3,595
Out of 4,969 analysts
78
Total ratings
39.51%
Success rate
-14.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Overweight | $200 → $203 | $198.35 | +2.34% | 19 | Aug 8, 2025 | |
| REPL Replimune Group | Upgrades: Overweight | n/a | $5.94 | - | 2 | Jul 30, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $8.34 | - | 11 | Jun 26, 2025 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $31.37 | - | 1 | Mar 27, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.35 | - | 2 | Mar 26, 2025 | |
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $3.22 | - | 1 | Mar 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $7.90 | - | 5 | Feb 7, 2025 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $1.01 | - | 7 | Jan 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $25.96 | - | 2 | Jan 13, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $11.56 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $8.57 | +133.37% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.20 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.72 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.90 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.80 | +67.13% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $220 | $7.86 | +2,698.98% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.01 | +397.51% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $2.12 | +1,692.45% | 1 | Aug 12, 2022 |
Ascendis Pharma
Aug 8, 2025
Maintains: Overweight
Price Target: $200 → $203
Current: $198.35
Upside: +2.34%
Replimune Group
Jul 30, 2025
Upgrades: Overweight
Price Target: n/a
Current: $5.94
Upside: -
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.34
Upside: -
Zai Lab
Mar 27, 2025
Reiterates: Overweight
Price Target: n/a
Current: $31.37
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.35
Upside: -
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.22
Upside: -
Arvinas
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.90
Upside: -
ALX Oncology Holdings
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.01
Upside: -
IDEAYA Biosciences
Jan 13, 2025
Reiterates: Overweight
Price Target: n/a
Current: $25.96
Upside: -
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.56
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $8.57
Upside: +133.37%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.20
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.72
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.90
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.80
Upside: +67.13%
Sep 7, 2023
Reiterates: Overweight
Price Target: $220
Current: $7.86
Upside: +2,698.98%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.01
Upside: +397.51%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $2.12
Upside: +1,692.45%